Trademark Overview
On Monday, March 4, 2024, a trademark application was filed for CAYALM with the United States Patent and Trademark Office. The USPTO has given the CAYALM trademark a serial number of 98431797. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Friday, September 27, 2024. This trademark is owned by GLAXO GROUP LIMITED. The CAYALM trademark is filed in the Pharmaceutical Products category with the following description:
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders